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ABSTRACT
Background: Researchers have reported that parasite lactate dehydrogenase p(LDH)
could be used to determine chemo-sensitivity of plasmodia to compounds with known
or presumed antimalarial activities.
Objective: To determine the drug sensitivity profiles of field adopted malaria isolates
from Kisumu using p(LDH) instead of hapoxanthine assay.
Design: Prospective field and laboratory study.
Setting: Walter Reed, KEMRI malaria laboratory (Nairobi) and Kisumu District Hospital.
Subjects: Twelve field laboratory adopted isolates from Kisumu, five laboratory adopted
isolates from other regions in Africa and three reference strains from Walter Reed army
Institute of Research, Washington, DC.
Results: The p(LDH) enzyme assay was successfully used to measure the IC50 of six
antimalarial drugs, chloroquine, quinine, mefloquine, dehydroartemisinin, atovaquone
and halofantrine but was not successful with the four other antimalarial drugs,
doxycycline, azithromycin, pyrimethamine and sulphadoxine. The Kisumu isolates tested
were resistant to chloroquine and mefloquine but sensitive to quinine and the new
antimalarial drugs, atovaquone, halofantrine and dehydroartemisinin.
Conclusion: The non-radioactive p(LDH) can be used for the determination of drug
sensitivity to Kenyan field isolates. It is more suited for use in a resource limited
environment and may lead to more judicious prescription of new and more expensive
antimalarial drugs and mitigate against the rapid spread of multi-drug resistant parasites
in the East African region.
INTRODUCTION
The unique ability of plasmodial lactate
dehydrogenase p(LDH) to utilise 3-acetyl pyridine
dinucleotide (APAD) in lieu of NAD as a co-enzyme
in the conversion of pyruvate to lactate, led to the
development of a biochemical assay for the detection
of plasmodial parasitaemia (1,2). It was further shown
that this assay could be used for the determination of
the chemo-sensitivity of plasmodia to compounds with
known or presumed antimalarial activities (1,3). Delay
in the institution of effective chemotherapy can lead
to higher complication rates and prolonged hospital stay
(4). One of the ways to reduce this cycle is the rational
use of antimalarial drugs and routine sensitivity testing
must be an integral part of any such antimalarial drug-
use programme.
The determination of parasite chemosensitivity to
antimalarial compounds is presently determined by a
variation of two basic techniques  the schizont inhibition
and the 3H-hypoxanthine uptake microtest (5). The
former requires microscopy for scoring and is not
suitable for high throughout due to observer bias and
fatigue. On the other hand, hypoxanthine uptake
technique requires radio labelled materials, is expensive
and cumbersome for routine clinical laboratory use. In
contrast, p(LDH) assay is a non-radio labelled
biochemical microtest with objective end-points
determined with an ELISA reader (1).
In vitro studies in Kenya revealed that significantly
more isolates were sensitive to amodiaquine compared
to chloroquine (6). Hence, amodiaquine was
recommended to replace chloroquine in Kenya because
of its demonstrated efficacy, reduced therapeutic toxicity
and low cost in the face of chloroquine resistance
(7,8). Fansidar was recommended to remain a reasonable
choice for treatment of blood slide - confirmed 4-
aminoquinoline resistant malaria, and quinine to be
retained for severe or complicated malaria before new
drugs are made affordable and available (9). Comparative
studies have shown that dehydroartemisinin predictably
give faster parasite and fever clearance than other
antimalarial drugs (10). Successful trials have also been
carried out with atovaquone, a hydroxynaphthoquinone,
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anti-parasitic drug for the treatment of malaria,
toxoplasmosis, and neumocystis carinii pneumonia (11).
This study was undertaken to assess the usefulness of
the p(LDH) assay for the determination of in vitro drug
sensitivity of Kenyan isolates against these six
antimalarial drugs.
MATERIALS AND METHODS
Parasite isolates used in the study included, KS140,
KS041, KS021, KS155, KS157, KS211, KS012, KS031,
KS168, KS047, KS063 and KS193 which were collected from
malaria patients in Kisumu, Kenya. Each isolate was transported
to the laboratory using transport media (5). Other isolates
Som A6 (Somali strain), M24 (Mombasa strain), FCB were
donated by the Wellcome Trust Research Laboratories,
Kenya. KS39 and S104 were culture adopted P. falciparum
isolates stored in liquid nitrogen (KEMRI malaria laboratory;
Immunology section). These isolates, identified as
P. falciparum were cultivated using standard techniques (1).
Parasitaemias were assessed using both thin and thick smear
procedures as well as p(LDH) and tritiated hypoxanthine
uptake. When parasitaemias were above 1%, drug tests were
set up after diluting the cultures to initial parasitaemia of
0.2% or 0.4% depending on the drug to be tested and the
incubation period for the drug (48 or 66 hours).
The reagents used in this study for p(LDH) analysis
were obtained from Sigma (St. Louis, Mo) and included
lithium lactate, trizma buffer, triton X-100, nitroblue
tetrazolium (NBT), phenazine ethosulphate (PES), 3- acetyl
pyridine dinucleotide (APAD) and nucleic acid(NAD). The
malstat reagent, which is a formulation for parasite LDH
detection, was obtained from flow, Inc. (Portland, OR.) and
used as outlined earlier (1). The RPMI 1640 medium was
obtained from Amersham International (Buckinghamshire,
U.K). The pre-dosed microtitre drug test plates were ordered
from WHO regional office, Manila (The Philippines) and
included, chloroquine, amodiaquine, quinine, pyrimethamine
and sulfadoxine. Later, drug plates were prepared in KEMRI
laboratories using WHO standard procedures for the drugs,
chloroquine, mefloquine, quinine, dehydroartemisinin,
atovaquone, halofantrine, doxycycline, azythromycin,
pyrimethamine and sulfadoxine.
Sensitivity assays: All assays were performed in triplicates.
Eight-fold 1 in 2 serial dilutions of drugs were distributed
into a 96-well microtitre plates in which fresh and infected
erythrocytes were added to give a volume of 200 µl well
and initial parasitaemia of 0.2% or 0.4% depending on the
time of incubation (48 or 66 hours) and the drugs for testing.
Control wells with uninfected erythrocytes and infected
erythrocytes in medium without drugs were always included
in each plate to monitor parasite growth, 100µl  of prepared
culture medium was mixed with an equal amount of the
starting concentration of the drug. A two fold dilution was
carried out up to well number ten, and the remaining
medium discarded. The 96 well drug plates were divided
into three chambers to allow for multiple comparative
studies, that is: chamber l (A, B, C) for hypoxanthine
studies; chamber 2 (D, E, F) for p(LDH) studies while the
last chamber(G,H) was for microscopy. Plates were incubated
at 37°C for 24 hours in a humidified chamber in the gas
mixture, following which 10 µ l per well 0.5 µci of 3H
hypoxanthine was added to the correct wells (5) and the
trays were incubated for a further 24 hours for the
hypoxanthine assay. The 48-hour isotopic microtest was
performed according to the modified method (5).
Measurement of drug sensitivity profiles for used and
candidate antimalarial drugs using parasite lactate
dehydrogenase p(LDH) assay: The parasite lactate
dehydrogenase assay was performed as a 48 hour test without
3H-hypoxanthine addition. The fast acting drugs were set at
0.2% initial parasitaemia for 48 hours. These included
chloroquine, starting concentration 100ng/ ml, mefloquine
100ng/ml, halofantrine, l0ng/ml, quinine, 500ng/ml,
dehydroartemisinin, l0ng/ml and atovaquone, l0ng/ml. The
slow acting drugs were set at 0.4 % initial parasitaemia, for
66 hours. These included doxycycline 1000ng/ml, azythromycin
10,000 ng/ml, sulfadoxine 10,000ng/ml and pyrimethamine
250 ng/ml. At the end of the incubation period, 50 µl of 1%
parasitised red blood cells of each isolate were put in 96 well
microtitre plates (incubated for 20 minutes with 100µl  of
malstat reagent). Equal volumes of nitroblue tetrazolium
(NBT) and phenazine ethosulphate (PES) were mixed and
10µl of fresh mixture added to each well and incubated in
the dark for 20 minutes. The plate was read at optical density
650nm wavelength after the reaction was stopped, with 5%
acetic acid (1). The blue formazan product was evaluated by
end point analysis at 650 nm using ELISA reader (Molecular
Devices Thermomax 7). The p(LDH) data was then analysed
by log-logit method using softmax nine software that directly
extrapolated the titration data of the drugs (1). The IC50
values were expressed in nanograms per mililitre (ng/ml) of
test culture. The p(LDH) assay was run for each isolate with
or without the drug in the 96-well culture plates. The
reference strains with known drug sensitivity profiles for
chloroquine and mefloquine D6 (chloroquine sensitivity,
mefloquine resistant) and W2 (chloroquine resistant,
mefloquine sensitive) served as controls for the wells with
or without drug assays (1).
Statistical analysis: Analysis of variance (ANOVA) was
used to compare the IC50 values between drugs and between
isolates. Means were separated using the SNK test. All tests
were carried out at 5% level of significance.
RESULTS
Table 1 shows the IC50s of the isolates for the
different drugs. For chloroquine only isolate KS044
was significantly higher than the resistant standard W2,
suggesting that this isolate is highly resistant to the
drug. Isolates KS063 and KS155 were also resistant.
Other isolates were not significantly different from the
susceptible D6. All the isolates tested were sensitive
to quinine though at different levels of IC50 values.
The isolates showed three categories of response to the
drug. Isolates, KS012, KS193, KS031, and D6 were
the first group: most sensitive in decreasing order;
isolates, W2, KS157, KS168, KS068, KS211, KS047
and KS044 were in group two: nearly sensitive though
not significantly different from the first group; and the
third group, KS155, had the highest reading though not
significantly different from the second group. Isolate
KS211 had the highest mean IC50, for
dehydroartemisinin though this was not significantly
different from KS193 and KS044. The other isolates,
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including the reference strains, D6 and W2 were highly
sensitive to very low doses of dehydroartemisinin. Only
two field isolates and the reference strains could be
replicated for atovaquone. The three isolates, KS044,
KS155 and W2 were sensitive to atovaquone, though
D6 gave the lowest sensitivity level with this drug.
Table 1
Mean ± S.E. IC5O (ng/ml) p(LDH) values for chloroquine (CQ), mefloquine, quinine and
dehydroartemisinin for different field isolates and two reference isolates
Isolate Mean IC50 Mean IC50 ± SE Mean IC50 ± SE        Mean IC50 ± SE
± SE Chloroquine Mefloquine Quinine                 Dehydroartemisinin
D6 6.33b ± 0.76 14.08a ± 5.54 41.33b ± 6.10 0.48c ± 0.089
KS044 67.82a ± 50.90 9.95a ± 3.44 58.45ab ± 18.70 0.56bc ± 0.29
KS063 36.65ab ± 9.95 17.88a ± 10.12 47.30ab ± 10.70 0.19c ± 0.01
KSI55 34.21ab ± 6.4 7.41a ± 1.06 87.57a ± 15.65 0.20c ± 0.095
KS00I 23.40b ± 7.80 1.90a ± 0.60 - -
KS168 3.32b ± 0.80 5.44a ± 2.22 46.82ab ± 16.60 0.54c ± 0.29
KS157 14.96b ± 7.11 3.92a ± 2.46 44.70ab ± 7.40 0.22c ± 0.05
KS012 14.37b ± 4.40 18.07a ± 2.77 22.26b ± 5.00 0.50c ± 0.032
KS211 7.93b ± 2.74 15.09a ± 5.70 52.55ab ± 5.40 1.38a ± 0.99
KS031 7.83b ± 1.74 9.38a ± 2.32 35.68b ± 14.00 0.33c ± 0.042
KS193 4.74b ± 1.13 7.48a ± 2.09 24.80b ± 9.70 1.26ab ± 0.50
KS047 4.08b ± 0.84 8.02a ± 4.44 53.36ab ± 27.00 0.56c ± 0.17
W2 16.57b ± 2.28 9.34a ± 1.76 45.10ab ± 8.40 0.54c ± 0.12
The means within a column followed by the same letter are not significantly different (SNK, p=0.05).
Table 2
Summary of measurement of mean IC50 (in ng/ml) p(LDH) values for six antimalarial drugs
Drug Field parasites combined Reference strain D6 Reference strain W2
Chloroquine 19.56 ± 4.17 6.33bc ± 0.75 16.57b ± 2.27
Mefloquine 9.83bc ± 1.19 14.08b ± 5.50 9.34b ± 1.76
Quinine 45.37a ± 4.95 41.33a ± 6.10 45.1a ± 8.4
Dehydroartemisinin 0.49c ± 0.08 0.48c ± 0.09 0.54b ± 0.12
Atovaquone 0.36c ± 0.03 0.14c ± 0.04 0.33b ± 0.06
Halofantrine 1.47c ± 0.44 - -
The means within a column followed by the same letter are not significantly different (SNK, p=0.05)
Table 3
IC50s of drugs which failed to give reproducible results by p(LDH)
Reference strain Doxycycline Azithromycin Pyrimethamine Sulfadoxine
(l000ng/ml) (10,000ng/ml) (250ng/ml) (10,000ng/ml)
D6 F 10000 0.0137 6090
8300 2900 F F
391 2970 267.00 F
1690 1700 30.40 F
1560 546 9400.00 F
F 786 3.820 F
2190 391 0.840 F
2490 1800 34.500 F
W2 4490 3300 249.000 110
F 2490 2.270 0.00013
39500 25000 9.180 F
19200 10800 2.280 19500
2300 6250 0.083 F
0.0059 3130 62.500 F
2360 2070 0.0091 F
F F F F
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Table 2 shows the IC50 values of each drug for
all the field isolates combined and the reference strains.
For the field isolates combined, quinine had the highest
overall IC50, which was significantly different from all
others. Chloroquine was next highest, but not
significantly different from mefloquine. All the other
drugs tested had very low over-all IC50 values, which
were not significantly different. For the reference
strains, quinine had a significantly higher IC50 value
than the other drugs. Both chloroquine and mefloquine
were similar. Mefloquine was significantly different
from the other two drugs (dehydroartemisinin and
atovaquone) for D6 but not for W2. Four drugs,
doxycycline, azithromycin, pyrimethamine and
sulfadoxine failed to give reproducible IC50 results
using the reference strains, and were therefore not
tested further for p(LDH) drug sensitivity. In most
experiments the drugs failed to produce a standard
curve by the log-logit method (Table 3).
DISCUSSION
The results of this study clearly indicate that the
sensitivity patterns of Kenyan isolates to chloroquine,
mefloquine, quinine and halofantrine can be determined
using the p(LDH) assay. The 50% inhibitory
concentration (IC50) was defined as the concentration
at which the p(LDH) produced by the parasites
(positively correlated with the number of viable parasites)
was inhibited by 50% as compared with the drug free
control wells. Failures of some isolates to give successful
p(LDH)lC50 was probably due to a low level of
parasitaemia in the drug plates, making it impossible
for the extrapolation of the IC50 using log-logit by soft
max nine software (1,12). There were also some field
isolates which failed to grow, probably due to an
inherent incapacity of certain isolates to adapt to in
vitro culture conditions (5). This observation of the
limitation of p(LDH) for drug susceptibility due to low
level parasitaemia was also reported in previous studies
(13,14). The study also cited the major limitation of
the enzymatic test as its level of sensitivity to detect
malarial LDH (15).
This study was carried out at a haematocrit of 1%,
and a significant LDH activity was not observed at a
parasitaemia of below 1%. In the culture adapted field
isolates, the initial parasitaemia of which a sigmoid
curve could be plotted for LDH activity was <0.4%,
the same cut-off reported earlier following in vitro
studies. The drug sensitivity studies were carried out
using haematocrit of 1%, 2% and 3%. By increasing
haematocrit, the human LDH background effect was
also increased making it difficult to visualise the
p(LDH) readings. The results suggest that the enzymatic
assay can be applied for in vitro drug screening using
culture adapted P. falciparum clones (D6, W2), and
also to an extent, by using culture adapted P. falciparum
field isolates.
The IC50 values obtained for quinine, mefloquine,
halofanthrine, chloroquine, dehydroartemisinin and
atovaquone against P. falciparum were within susceptible
range (16,17,10). This attests to the potential of the
drug atovaquine, a broad spectrum anti-infective agent
for clinical use against malaria and opportunistic
infections in AIDS patients (16). An increase in sample
size is likely to give a better picture of the anti-malarial
drug resistant pattern in Western Kenya. These isolates
were collected from Kisumu, a malaria endemic region
in Western Kenya. Carrying out the same study in other
parts of the country like the coastal and the highlands
region is likely to give a more complete picture of the
drug susceptibility pattern in the country and potentially
lead to a comprehensive and rational policy for malaria
treatment and prophylaxis. No study has previously
reported on drug sensitivity profiles of Kenyan isolates
by use of p(LDH) assay against the six antimalarial
drugs tested. By incorporating the reference strains (D6
and W2) and culture adapting the field isolates the
present study has provided a reference point for drug
sensitivity studies for the field isolates from the surveyed
population. Perhaps the difficulty associated with culture
adapting the field isolates could be one possible reason
why such studies were not carried out earlier. Adaptation
takes an average of two to three weeks, it is expensive
in time and materials to attain large numbers of
parasites that can be used for the susceptibility studies.
However, this is nothing compared to the cost in human
life and suffering - the result of the administration of
wrong drugs in the wake of drug resistance in these
parts of the country. Therapy and treatment based on
the susceptibility profile of the isolate saves time and
money and hence minimize drug pressure against new
and expensive antimalarial drugs like halofantrine,
dehydroartemisinin and atovaquone. Plasmodia anti-
malarial drug susceptibility is a dynamic process (18)
that is dependent on various factors to include changes
in drug pressure. Hence, there is need for a simple,
rapid and cost effective tool like the p(LDH) assay for
monitoring parasite drug susceptibility profiles. Fansidar
has replaced chloroquine as the first line drug in the
treatment of uncomplicated malaria in most parts of
Kenya. However, our study indicates that not all
Kisumu isolates are chloroquine resistant. Therefore,
the availability of a cost effective screening assay for
chloroquine resistance can favourably impact the clinical
management of malaria in that hyper-endemic region
of Kenya where it would save not only scarce healthcare
resources but human life.
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